Volume 43 Issue 3
May  2022
Turn off MathJax
Article Contents
Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Jian-Ru Qin, Qi-Hong Yan, Xia Jin, Xin-Wen Chen, Yong-Tang Zheng, Jin-Cun Zhao, Jian-Hua Wang. Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice. Zoological Research, 2022, 43(3): 457-468. doi: 10.24272/j.issn.2095-8137.2021.469
Citation: Meng-Li Wu, Feng-Liang Liu, Jing Sun, Xin Li, Jian-Ru Qin, Qi-Hong Yan, Xia Jin, Xin-Wen Chen, Yong-Tang Zheng, Jin-Cun Zhao, Jian-Hua Wang. Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice. Zoological Research, 2022, 43(3): 457-468. doi: 10.24272/j.issn.2095-8137.2021.469

Combinational benefit of antihistamines and remdesivir for reducing SARS-CoV-2 replication and alleviating inflammation-induced lung injury in mice

doi: 10.24272/j.issn.2095-8137.2021.469
#Authors contributed equally to this work
Funds:  This work was supported by the National Natural Science Foundation of China (82172242, 81873965), State Key Laboratory of Respiratory Disease, Guangzhou, China (SKLRD-OP-202207), National Key R&D Program of China (2020YFC0842000), Natural Science Foundation of Guangdong (2022A1515012053), and Key Project from the Chinese Academy of Sciences (QYZDB-SSW-SMC059)
More Information
  • COVID-19 is an immune-mediated inflammatory disease caused by SARS-CoV-2 infection, the combination of anti-inflammatory and antiviral therapy is predicted to provide clinical benefits. We recently demonstrated that mast cells (MCs) are an essential mediator of SARS-CoV-2-initiated hyperinflammation. We also showed that spike protein-induced MC degranulation initiates alveolar epithelial inflammation for barrier disruption and suggested an off-label use of antihistamines as MC stabilizers to block degranulation and consequently suppress inflammation and prevent lung injury. In this study, we emphasized the essential role of MCs in SARS-CoV-2-induced lung lesions in vivo, and demonstrated the benefits of co-administration of antihistamines and antiviral drug remdesivir in SARS-CoV-2-infected mice. Specifically, SARS-CoV-2 spike protein-induced MC degranulation resulted in alveolar-capillary injury, while pretreatment of pulmonary microvascular endothelial cells with antihistamines prevented adhesion junction disruption; predictably, the combination of antiviral drug remdesivir with the antihistamine loratadine, a histamine receptor 1 (HR1) antagonist, dampened viral replication and inflammation, thereby greatly reducing lung injury. Our findings emphasize the crucial role of MCs in SARS-CoV-2-induced inflammation and lung injury and provide a feasible combination antiviral and anti-inflammatory therapy for COVID-19 treatment.
  • #Authors contributed equally to this work
  • loading
  • [1]
    Abdelaziz MM, Khair OA, Devalia JL. 2000. The potential of active metabolites of antihistamines in the management of allergic disease. Allergy, 55(5): 425−434. doi: 10.1034/j.1398-9995.2000.00114.x
    [2]
    Abdelnabi R, Foo CS, Kaptein SJF, Zhang X, Do TND, Langendries L, et al. 2021. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. eBioMedicine, 72: 103595. doi: 10.1016/j.ebiom.2021.103595
    [3]
    Attiq A, Yao LJ, Afzal S, Khan MA. 2021. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. International Immunopharmacology, 101: 108255. doi: 10.1016/j.intimp.2021.108255
    [4]
    Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. 2020. Remdesivir for the treatment of covid-19 - final report. The New England Journal of Medicine, 383(19): 1813−1826. doi: 10.1056/NEJMoa2007764
    [5]
    Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, et al. 2021. Improved survival among hospitalized patients with coronavirus disease 2019 (COVID-19) treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clinical Infectious Diseases, 73(11): 2031−2036. doi: 10.1093/cid/ciab536
    [6]
    Biswas P, Hasan MM, Dey D, Dos Santos Costa AC, Polash SA, Bibi S, et al. 2021. Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. Environmental Science and Pollution Research, 28(42): 59570−59593. doi: 10.1007/s11356-021-16096-3
    [7]
    Chen NS, Zhou M, Dong X, Qu JM, Gong FY, Han Y, et al. 2020. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, 395(10223): 507−513. doi: 10.1016/S0140-6736(20)30211-7
    [8]
    Chen T, Fei CY, Chen YP, Sargsyan K, Chang CP, Yuan HS, et al. 2021. Synergistic inhibition of SARS-CoV-2 replication using disulfiram/ebselen and remdesivir. ACS Pharmacology & Translational Science, 4(2): 898−907.
    [9]
    Da Silva Motta Junior J, Dos Santos Miggiolaro AFR, Nagashima S, De Paula CBV, Baena CP, Scharfstein J, et al. 2020. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Frontiers in Immunology, 11: 574862. doi: 10.3389/fimmu.2020.574862
    [10]
    Daher J. 2021. Endothelial dysfunction and COVID-19 (Review). Biomedical Reports, 15(6): 102. doi: 10.3892/br.2021.1478
    [11]
    De Clercq E. 2021. Remdesivir: Quo vadis?. Biochemical Pharmacology, 193: 114800. doi: 10.1016/j.bcp.2021.114800
    [12]
    Dos Santos Miggiolaro AFR, Da Silva Motta Junior J, De Paula CBV, Nagashima S, Malaquias MAS, Carstens LB, et al. 2020. Covid-19 cytokine storm in pulmonary tissue: Anatomopathological and immunohistochemical findings. Respiratory Medicine Case Reports, 31: 101292. doi: 10.1016/j.rmcr.2020.101292
    [13]
    Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. 2020. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology, 159(3): 1129−1131.E3. doi: 10.1053/j.gastro.2020.05.053
    [14]
    Garibaldi BT, Wang KB, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, et al. 2021. Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19. JAMA Network Open, 4(3): e213071. doi: 10.1001/jamanetworkopen.2021.3071
    [15]
    Giudice V, Pagliano P, Vatrella A, Masullo A, Poto S, Polverino BM, et al. 2020. Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Frontiers in Pharmacology, 11: 857. doi: 10.3389/fphar.2020.00857
    [16]
    Hogan II RB, Hogan III RB, Cannon T, Rappai M, Studdard J, Paul D, et al. 2020. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. Pulmonary Pharmacology & Therapeutics, 63: 101942.
    [17]
    Huang CL, Huang LX, Wang YM, Li X, Ren LL, Gu XY, et al. 2021. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet, 397(10270): 220−232. doi: 10.1016/S0140-6736(20)32656-8
    [18]
    Hung IFN, Lung KC, Tso EYK, Liu R, Chung TWH, Chu MY, et al. 2020. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The Lancet, 395(10238): 1695−1704. doi: 10.1016/S0140-6736(20)31042-4
    [19]
    Iaboni A, Wong N, Betschel SD. 2021. A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma. Journal of Clinical Immunology, 41(5): 923−925. doi: 10.1007/s10875-021-00983-y
    [20]
    Itoh K, Sakamaki I, Hirota T, Iwasaki H. 2022. Evaluation of minocycline combined with favipiravir therapy in coronavirus disease 2019 patients: a case-series study. Journal of Infection and Chemotherapy, 28(1): 124−127. doi: 10.1016/j.jiac.2021.09.016
    [21]
    Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, et al. 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut, 69(9): 1592−1597. doi: 10.1136/gutjnl-2020-321852
    [22]
    Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. 2021. Baricitinib plus remdesivir for hospitalized adults with covid-19. The New England Journal of Medicine, 384(9): 795−807. doi: 10.1056/NEJMoa2031994
    [23]
    Komi DEA, Wöhrl S, Bielory L. 2020. Mast cell biology at molecular level: a comprehensive review. Clinical Reviews in Allergy & Immunology, 58(3): 342−365.
    [24]
    Konkolova E, Dejmek M, Hřebabecký H, Šála M, Böserle J, Nencka R, et al. 2020. Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses. Antiviral Research, 182: 104899. doi: 10.1016/j.antiviral.2020.104899
    [25]
    Lam HY, Tergaonkar V, Kumar AP, Ahn KS. 2021. Mast cells: therapeutic targets for COVID-19 and beyond. IUBMB Life, 73(11): 1278−1292. doi: 10.1002/iub.2552
    [26]
    Mahase E. 2021a. Covid-19: molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ, 375: n2422.
    [27]
    Mahase E. 2021b. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ, 375: n2713.
    [28]
    Mahase E. 2021c. Covid-19: UK becomes first country to authorise antiviral molnupiravir. BMJ, 375: n2697.
    [29]
    Malone RW, Tisdall P, Fremont-Smith P, Liu YF, Huang XP, White KM, et al. 2021. COVID-19: famotidine, histamine, mast cells, and mechanisms. Frontiers in Pharmacology, 12: 633680. doi: 10.3389/fphar.2021.633680
    [30]
    Marfe G, Perna S, Shukla AK. 2021. Effectiveness of COVID-19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 22(6): 1407. doi: 10.3892/etm.2021.10843
    [31]
    Mather JF, Seip RL, McKay RG. 2020. Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19. The American Journal of Gastroenterology, 115(10): 1617−1623. doi: 10.14309/ajg.0000000000000832
    [32]
    Monteil V, Dyczynski M, Lauschke VM, Kwon H, Wirnsberger G, Youhanna S, et al. 2021. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Molecular Medicine, 13(1): e13426.
    [33]
    Mouffak S, Shubbar Q, Saleh E, El-Awady R. 2021. Recent advances in management of COVID-19: a review. Biomedicine & Pharmacotherapy, 143: 112107.
    [34]
    Mukherjee R, Bhattacharya A, Bojkova D, Mehdipour AR, Shin D, Khan KS, et al. 2021. Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. Journal of Biological Chemistry, 297(2): 100925. doi: 10.1016/j.jbc.2021.100925
    [35]
    Murdaca G, Di Gioacchino M, Greco M, Borro M, Paladin F, Petrarca C, et al. 2021. Basophils and mast cells in COVID-19 pathogenesis. Cells, 10(10): 2754. doi: 10.3390/cells10102754
    [36]
    Pruijssers AJ, George AS, Schäfer A, Leist SR, Gralinksi LE, Dinnon KH III, et al. 2020. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Reports, 32(3): 107940. doi: 10.1016/j.celrep.2020.107940
    [37]
    Qin C, Zhou LQ, Hu ZW, Zhang SQ, Yang S, Tao Y, et al. 2020. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases, 71(15): 762−768. doi: 10.1093/cid/ciaa248
    [38]
    Rauti R, Shahoha M, Leichtmann-Bardoogo Y, Nasser R, Paz E, Tamir R, et al. 2021. Effect of SARS-CoV-2 proteins on vascular permeability. eLife, 10: e69314. doi: 10.7554/eLife.69314
    [39]
    Rochwerg B, Agarwal A, Zeng LN, Leo YS, Appiah JA, Agoritsas T, et al. 2020. Remdesivir for severe covid-19: a clinical practice guideline. BMJ, 370: m2924.
    [40]
    Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. 2021. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Medicine, 47(11): 1258−1270. doi: 10.1007/s00134-021-06507-x
    [41]
    Rubin D, Chan-Tack K, Farley J, Sherwat A. 2020. FDA approval of remdesivir - a step in the right direction. New England Journal of Medicine, 383(27): 2598−2600. doi: 10.1056/NEJMp2032369
    [42]
    Schloer S, Brunotte L, Mecate-Zambrano A, Zheng SY, Tang J, Ludwig S, et al. 2021. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. British Journal of Clinical Pharmacology, 178(11): 2339−2350. doi: 10.1111/bph.15418
    [43]
    Shuai HP, Chan JFW, Yuen TTT, Yoon C, Hu JC, Wen L, et al. 2021. Emerging SARS-CoV-2 variants expand species tropism to murines. eBioMedicine, 73: 103643. doi: 10.1016/j.ebiom.2021.103643
    [44]
    Slater JW, Zechnich AD, Haxby DG. 1999. Second-generation antihistamines: a comparative review. Drugs, 57(1): 31−47. doi: 10.2165/00003495-199957010-00004
    [45]
    Song TZ, Zheng HY, Han JB, Jin L, Yang X, Liu FL, et al. 2020. Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zoological Research, 41(5): 503−516. doi: 10.24272/j.issn.2095-8137.2020.202
    [46]
    Stegmann KM, Dickmanns A, Gerber S, Nikolova V, Klemke L, Manzini V, et al. 2021. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. Virus Research, 302: 198469. doi: 10.1016/j.virusres.2021.198469
    [47]
    Tian RR, Yang CX, Zhang M, Feng XL, Luo RH, Duan ZL, et al. 2021. Lower respiratory tract samples are reliable for severe acute respiratory syndrome coronavirus 2 nucleic acid diagnosis and animal model study. Zoological Research, 42(2): 161−169. doi: 10.24272/j.issn.2095-8137.2020.329
    [48]
    Wang DW, Hu B, Hu C, Zhu FF, Liu X, Zhang J, et al. 2020a. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323(11): 1061−1069. doi: 10.1001/jama.2020.1585
    [49]
    Wang P, Luo RH, Zhang M, Wang YQ, Song TZ, Tao TT, et al. 2020b. A cross-talk between epithelium and endothelium mediates human alveolar-capillary injury during SARS-CoV-2 infection. Cell Death & Disease, 11(12): 1042.
    [50]
    Wang YM, Zhang DY, Du GH, Du RH, Zhao JP, Jin Y, et al. 2020c. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395(10236): 1569−1578. doi: 10.1016/S0140-6736(20)31022-9
    [51]
    Wu ML, Liu FL, Sun J, Li X, He XY, Zheng HY, et al. 2021. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. Signal Transduction and Targeted Therapy, 6(1): 428. doi: 10.1038/s41392-021-00849-0
    [52]
    Xu L, Yu DD, Ma YH, Yao YL, Luo RH, Feng XL, et al. 2020. COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. Zoological Research, 41(5): 517−526. doi: 10.24272/j.issn.2095-8137.2020.053
    [53]
    Ye ZW, Yuan SF, Chan JFW, Zhang AJ, Yu CY, Ong CP, et al. 2021. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Emerging Microbes & Infections, 10(1): 291−304.
    [54]
    Zhou YY, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. 2019. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications, 10(1): 1523. doi: 10.1038/s41467-019-09234-6
  • ZR-2021-469-Supplementary Materials.pdf
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)

    Article Metrics

    Article views (387) PDF downloads(70) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return